Yassine Kilani, Mohammad Aldiabat, Kym Yves T Sirilan, Ahmad Basil Nasir, Mahmoud Y Madi, Wing-Kin Syn
{"title":"masld对自身免疫性肝炎结局的影响：全国2880例记录分析","authors":"Yassine Kilani, Mohammad Aldiabat, Kym Yves T Sirilan, Ahmad Basil Nasir, Mahmoud Y Madi, Wing-Kin Syn","doi":"10.14309/ctg.0000000000000912","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite the growing recognition of autoimmune hepatitis (AIH) - Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) overlap, studies today are limited by small sample sizes. This study aimed to investigate the impact of MASLD on the outcomes of patients with AIH using large-scale real world data.</p><p><strong>Methods: </strong>This cohort study used the TriNetX research network to identify U.S. adults (≥18 years) with AIH. Patients were stratified into those with MASLD (AIH-MASLD cohort), and controls (AIH without MASLD). Propensity score matching (1:1) between AIH-MASLD and controls accounted for demographics, comorbidities, and treatments. Outcomes were classified as short-term (within 1 year after diagnosis) or long-term (within 10 years) outcomes.</p><p><strong>Results: </strong>Among 4,798 records with AIH, 1,440 AIH-MASLD patients were propensity matched with 1,440 controls. AIH-MASLD patients demonstrated reduced one-year odds of all-cause mortality (HR = 0.66, 95%CI: 0.44 - 0.98), and immunosuppressive medication use (HR = 0.69, 95%CI: 0.63 - 0.76), along with increased 10-year odds of cirrhosis (HR = 1.22, 95%CI: 1.06 - 1.40) and hepatocellular carcinoma (HR = 2.03, 95%CI: 1.09 - 3.78) compared to controls.</p><p><strong>Conclusions: </strong>In summary, our study using real-world evidence showed a significant association between MASLD and worse clinical outcomes in patients with AIH. Future efforts should be targeted towards facilitating early detection and management of MASLD in AIH patients.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"THE IMPACT OF MASLD ON AUTOIMMUNE HEPATITIS OUTCOMES: A NATIONWIDE ANALYSIS OF 2880 RECORDS.\",\"authors\":\"Yassine Kilani, Mohammad Aldiabat, Kym Yves T Sirilan, Ahmad Basil Nasir, Mahmoud Y Madi, Wing-Kin Syn\",\"doi\":\"10.14309/ctg.0000000000000912\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Despite the growing recognition of autoimmune hepatitis (AIH) - Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) overlap, studies today are limited by small sample sizes. This study aimed to investigate the impact of MASLD on the outcomes of patients with AIH using large-scale real world data.</p><p><strong>Methods: </strong>This cohort study used the TriNetX research network to identify U.S. adults (≥18 years) with AIH. Patients were stratified into those with MASLD (AIH-MASLD cohort), and controls (AIH without MASLD). Propensity score matching (1:1) between AIH-MASLD and controls accounted for demographics, comorbidities, and treatments. Outcomes were classified as short-term (within 1 year after diagnosis) or long-term (within 10 years) outcomes.</p><p><strong>Results: </strong>Among 4,798 records with AIH, 1,440 AIH-MASLD patients were propensity matched with 1,440 controls. AIH-MASLD patients demonstrated reduced one-year odds of all-cause mortality (HR = 0.66, 95%CI: 0.44 - 0.98), and immunosuppressive medication use (HR = 0.69, 95%CI: 0.63 - 0.76), along with increased 10-year odds of cirrhosis (HR = 1.22, 95%CI: 1.06 - 1.40) and hepatocellular carcinoma (HR = 2.03, 95%CI: 1.09 - 3.78) compared to controls.</p><p><strong>Conclusions: </strong>In summary, our study using real-world evidence showed a significant association between MASLD and worse clinical outcomes in patients with AIH. Future efforts should be targeted towards facilitating early detection and management of MASLD in AIH patients.</p>\",\"PeriodicalId\":10278,\"journal\":{\"name\":\"Clinical and Translational Gastroenterology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14309/ctg.0000000000000912\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000912","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
THE IMPACT OF MASLD ON AUTOIMMUNE HEPATITIS OUTCOMES: A NATIONWIDE ANALYSIS OF 2880 RECORDS.
Background: Despite the growing recognition of autoimmune hepatitis (AIH) - Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) overlap, studies today are limited by small sample sizes. This study aimed to investigate the impact of MASLD on the outcomes of patients with AIH using large-scale real world data.
Methods: This cohort study used the TriNetX research network to identify U.S. adults (≥18 years) with AIH. Patients were stratified into those with MASLD (AIH-MASLD cohort), and controls (AIH without MASLD). Propensity score matching (1:1) between AIH-MASLD and controls accounted for demographics, comorbidities, and treatments. Outcomes were classified as short-term (within 1 year after diagnosis) or long-term (within 10 years) outcomes.
Results: Among 4,798 records with AIH, 1,440 AIH-MASLD patients were propensity matched with 1,440 controls. AIH-MASLD patients demonstrated reduced one-year odds of all-cause mortality (HR = 0.66, 95%CI: 0.44 - 0.98), and immunosuppressive medication use (HR = 0.69, 95%CI: 0.63 - 0.76), along with increased 10-year odds of cirrhosis (HR = 1.22, 95%CI: 1.06 - 1.40) and hepatocellular carcinoma (HR = 2.03, 95%CI: 1.09 - 3.78) compared to controls.
Conclusions: In summary, our study using real-world evidence showed a significant association between MASLD and worse clinical outcomes in patients with AIH. Future efforts should be targeted towards facilitating early detection and management of MASLD in AIH patients.
期刊介绍：
Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease.
Colon and small bowel
Endoscopy and novel diagnostics
Esophagus
Functional GI disorders
Immunology of the GI tract
Microbiology of the GI tract
Inflammatory bowel disease
Pancreas and biliary tract
Liver
Pathology
Pediatrics
Preventative medicine
Nutrition/obesity
Stomach.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
